E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Trial exploring biomarkers of the immune system under de novo therapy with Belatacept vs. Cyclosporine after kidney transplantation |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10062016 |
E.1.2 | Term | Immunosuppression |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To explore a number of biomarkers from plasma, serum and renal tissue to describe the impact of different strategies for immunosuppression (Belatacept, Cyclosporine) on the immune-system that may explain differences in long-term outcome. |
|
E.2.2 | Secondary objectives of the trial |
The main secondary objective is to evaluate the diagnostic accuracy of various biomarkers (FACs panel, chemokines and cytokines) regarding the relevancy of an acute rejection episode with lower tendency to relapse and without relevant deterioration of renal function in the follow up and having regard to the randomly assigned immunosuppression.
Renal function of the graft was favorable by a delta eGFR of 10 ml/min after 36 months even in a trial with marginal kidney donations as compared to renal transplant recipients under Cyclosporine (Benefit extended trial). Using markers of kidney toxicity in plasma, renal tissue and urine, we will describe whether this effect was due to a lower kidney toxicity of the drug as compared to Cyclosporine.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and female patients scheduled to receive a single-organ renal transplant, 18 to 65 years old at the day of inclusion.
2. Transplant from a living or deceased donor aged under 65 years.
3. Patients must have IgG-detectable positive Epstein-Barr virus serostatus.
4. Patient must have signed the written informed consent.
5. Patients must have a current or historic panel reactive antibody ≤30% (according to Lymphocytotoxicity-Test. The antibody screening is back followed until patients` acceptance as KTRs on the waiting list).
6. Kidney donors must have a serum creatinine ≤ 1.5 mg/dl or 130 µmol/l.
7. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant must have a negative pregnancy test using serum performed immediately before tx.
8. Female patients must meet at least one of the following criteria:
• For female patients ≥ 50 years of age at the day of inclusion: Menopause since at least 1 year.
• For female patients < 50 years of age at the day of inclusion: Menopause since at least 1 year and serum FSH level > 40 mIU/mL.
• 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral ovariectomy with or without hysterectomy.
• Correct use of an effective method of birth control (locally acting hormonal contraceptives as vaginal products, skin patches, implanted or injectable products, mechanical products such as intrauterine devices or barrier methods as diaphragm, condoms, spermicides) during the study and until a minimum of 8 weeks after the last administration of investigational medicinal product. Oral hormonal contraceptives are not acceptable.
• General sexual abstinence during the study and until a minimum of 8 weeks after the last administration of investigational medicinal product.
• Having only female sexual partners.
• Relationships with only sterile male partners
9. Procreative male subjects should be advised to avoid unprotected sex throughout the study and until sperm produced during the period of drug exposure has been cleared (10 weeks).
|
|
E.4 | Principal exclusion criteria |
1. History of lymphoproliferative disease.
2. Patients with a proven or suspected history for tuberculosis who have not been previously treated for latent infections.
3. Patients with other transplanted organs (heart, liver, pancreas) or with a history of bone marrow transplantation.
4. Patients with previous renal graft.
5. Patients with a malignant disease.
6. Patients with an infectious hepatitis B or C or a positive HIV status.
7. Patients unable to give their written consent (e. g. stroke patients or those with severe dementia or mental disability).
8. Pregnant or lactating females.
9. Current participation in any other clinical trial and/or participation in another clinical trial within 30 days before the study begin.
10. Patients that are in a physical state that, in the opinion of the investigator, might interfere with the objectives of the study or pose additional risk to the patients due to participation in the study (e. g. patients with an elevated risk for bleeding* after kidney biopsy, patients with an immunological disease predisposing for rejection); *Hypocoagulability: thrombocytes < 100.000 /µl, Quick test < 70 % or INR < 2.0.
11. Patients with a severe cachexia (BMI < 16).
12. Patients with a history of allergy or drug reaction against the investigational medicinal products.
13. Patients receiving an ABO-incompatible kidney donation from a living donor.
14. Patients being pre-sensitized for donor specific antibodies before kidney transplantation using special lymphocyte depleting immunosuppressive protocols.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial is monitored by a committee independent by the investigators. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 30 |
E.8.9.1 | In the Member State concerned days | |